AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NCT06062823 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

NCT05466149 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

NCT03050411 ·Status: UNKNOWN ·Phase: PHASE1

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

NCT01746251 ·Status: UNKNOWN ·Phase: PHASE2

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

NCT04853342 ·Status: RECRUITING ·Phase: PHASE3

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

NCT03123484 ·Status: UNKNOWN ·Phase: PHASE2

Observational Study of Afatinib 30 mg Daily

NCT04909073 ·Status: RECRUITING

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

NCT04785742 ·Status: UNKNOWN ·Phase: PHASE2

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

NCT04206787 ·Status: COMPLETED

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06955988 ·Status: RECRUITING ·Phase: PHASE1

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02064491 ·Status: COMPLETED ·Phase: PHASE2

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

NCT05241028 ·Status: RECRUITING ·Phase: PHASE2

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT01480141 ·Status: WITHDRAWN ·Phase: PHASE2

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

NCT01953913 ·Status: COMPLETED ·Phase: PHASE3

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

NCT03461185 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

NCT01801111 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

NCT01714908 ·Status: UNKNOWN ·Phase: PHASE2

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

NCT02044380 ·Status: COMPLETED ·Phase: PHASE3

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

NCT04455594 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Retrospective Study of Biomarkers in Non-Small Cell Lung Cancer

NCT01100840 ·Status: UNKNOWN

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

NCT02438722 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT03054038 ·Status: TERMINATED ·Phase: PHASE1

The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer

NCT03129698 ·Status: UNKNOWN ·Phase: PHASE2

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

NCT02335944 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

NCT07298148 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2